{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:56:49Z","timestamp":1791219409694,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2022-KH128236"],"award-info":[{"award-number":["RS-2022-KH128236"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2022-KH128243"],"award-info":[{"award-number":["RS-2022-KH128243"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2022-KH128236"],"award-info":[{"award-number":["RS-2022-KH128236"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2022-KH128243"],"award-info":[{"award-number":["RS-2022-KH128243"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2022-KH128243"],"award-info":[{"award-number":["RS-2022-KH128243"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2022-KH128243"],"award-info":[{"award-number":["RS-2022-KH128243"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2022-KH128243"],"award-info":[{"award-number":["RS-2022-KH128243"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2022-KH128236"],"award-info":[{"award-number":["RS-2022-KH128236"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2022-KH128236"],"award-info":[{"award-number":["RS-2022-KH128236"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","award":["RS-2024-00337146"],"award-info":[{"award-number":["RS-2024-00337146"]}],"id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","award":["RS-2024-00337146"],"award-info":[{"award-number":["RS-2024-00337146"]}],"id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","award":["RS-2024-00337146"],"award-info":[{"award-number":["RS-2024-00337146"]}],"id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","award":["RS-2024-00337146"],"award-info":[{"award-number":["RS-2024-00337146"]}],"id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01225-7","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T07:02:50Z","timestamp":1753167770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A vaccine targeting lung resident-memory CD4+ T cell phenotype protects against Mycobacterium tuberculosis in mice"],"prefix":"10.1038","volume":"10","author":[{"given":"Kwang Hyun","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hun","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Shik","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Mi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Hwa","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Yeon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hye","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Gyu","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwa-Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Sun","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung","family":"Bin Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"1225_CR1","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/ni.1654","volume":"9","author":"H Gan","year":"2008","unstructured":"Gan, H. et al. Mycobacterium tuberculosis blocks crosslinking of annexin-1 and apoptotic envelope formation on infected macrophages to maintain virulence. Nat. Immunol. 9, 1189\u20131197 (2008).","journal-title":"Nat. Immunol."},{"key":"1225_CR2","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nrmicro1211","volume":"3","author":"P Andersen","year":"2005","unstructured":"Andersen, P. & Doherty, T. M. The success and failure of BCG\u2014implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol 3, 656\u2013662 (2005).","journal-title":"Nat. Rev. Microbiol"},{"key":"1225_CR3","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/S0140-6736(95)92348-9","volume":"346","author":"PE Fine","year":"1995","unstructured":"Fine, P. E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346, 1339\u20131345 (1995).","journal-title":"Lancet"},{"key":"1225_CR4","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jama.1994.03510330076038","volume":"271","author":"GA Colditz","year":"1994","unstructured":"Colditz, G. A. et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271, 698\u2013702 (1994).","journal-title":"JAMA"},{"key":"1225_CR5","volume":"2011","author":"JJ Nuttall","year":"2011","unstructured":"Nuttall, J. J. & Eley, B. S. BCG vaccination in HIV-infected children. Tuberc. Res Treat. 2011, 712736 (2011).","journal-title":"Tuberc. Res Treat."},{"key":"1225_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ijid.2015.01.014","volume":"32","author":"JD Fonseca","year":"2015","unstructured":"Fonseca, J. D., Knight, G. M. & McHugh, T. D. The complex evolution of antibiotic resistance in Mycobacterium tuberculosis. Int J. Infect. Dis. 32, 94\u2013100 (2015).","journal-title":"Int J. Infect. Dis."},{"key":"1225_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","volume":"21","author":"AJ Pollard","year":"2021","unstructured":"Pollard, A. J. & Bijker, E. M. A guide to vaccinology: from basic principles to new developments. Nat. Rev. Immunol. 21, 83\u2013100 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1225_CR8","doi-asserted-by":"publisher","first-page":"854507","DOI":"10.1155\/2015\/854507","volume":"2015","author":"IV Lyadova","year":"2015","unstructured":"Lyadova, I. V. & Panteleev, A. V. Th1 and Th17 Cells in Tuberculosis: Protection, Pathology, and Biomarkers. Mediators Inflamm. 2015, 854507 (2015).","journal-title":"Mediators Inflamm."},{"key":"1225_CR9","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.4049\/jimmunol.1701424","volume":"200","author":"IY Nikitina","year":"2018","unstructured":"Nikitina, I. Y. et al. Th1, Th17, and Th1Th17 Lymphocytes during Tuberculosis: Th1 Lymphocytes Predominate and Appear as Low-Differentiated CXCR3(+)CCR6(+) Cells in the Blood and Highly Differentiated CXCR3(+\/-)CCR6(-) Cells in the Lungs. J. Immunol. 200, 2090\u20132103 (2018).","journal-title":"J. Immunol."},{"key":"1225_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/mi.2011.14","volume":"4","author":"JL Flynn","year":"2011","unstructured":"Flynn, J. L., Chan, J. & Lin, P. L. Macrophages and control of granulomatous inflammation in tuberculosis. Mucosal Immunol. 4, 271\u2013278 (2011).","journal-title":"Mucosal Immunol."},{"key":"1225_CR11","doi-asserted-by":"publisher","first-page":"4689","DOI":"10.4049\/jimmunol.171.9.4689","volume":"171","author":"SC Cowley","year":"2003","unstructured":"Cowley, S. C. & Elkins, K. L. CD4+ T cells mediate IFN-gamma-independent control of Mycobacterium tuberculosis infection both in vitro and in vivo. J. Immunol. 171, 4689\u20134699 (2003).","journal-title":"J. Immunol."},{"key":"1225_CR12","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1128\/IAI.68.2.621-629.2000","volume":"68","author":"P Andersen","year":"2000","unstructured":"Andersen, P. & Smedegaard, B. CD4(+) T-cell subsets that mediate immunological memory to Mycobacterium tuberculosis infection in mice. Infect. Immun. 68, 621\u2013629 (2000).","journal-title":"Infect. Immun."},{"key":"1225_CR13","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1021\/acsabm.1c01238","volume":"5","author":"IW Hamley","year":"2022","unstructured":"Hamley, I. W. Peptides for vaccine development. ACS Appl Bio Mater. 5, 905\u2013944 (2022).","journal-title":"ACS Appl Bio Mater."},{"key":"1225_CR14","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/nrd2224","volume":"6","author":"AW Purcell","year":"2007","unstructured":"Purcell, A. W., McCluskey, J. & Rossjohn, J. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov. 6, 404\u2013414 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1225_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00005-010-0067-0","volume":"58","author":"DS Rosa","year":"2010","unstructured":"Rosa, D. S., Ribeiro, S. P. & Cunha-Neto, E. CD4+ T cell epitope discovery and rational vaccine design. Arch. Immunol. Ther. Exp. (Warsz.) 58, 121\u2013130 (2010).","journal-title":"Arch. Immunol. Ther. Exp. (Warsz.)"},{"key":"1225_CR16","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.cell.2018.08.048","volume":"175","author":"R Marty Pyke","year":"2018","unstructured":"Marty Pyke, R. et al. Evolutionary pressure against MHC class II binding cancer mutations. Cell 175, 416\u2013428.e413 (2018).","journal-title":"Cell"},{"key":"1225_CR17","doi-asserted-by":"publisher","first-page":"e1005760","DOI":"10.1371\/journal.ppat.1005760","volume":"12","author":"CS Lindestam Arlehamn","year":"2016","unstructured":"Lindestam Arlehamn, C. S. et al. A quantitative analysis of complexity of human pathogen-specific CD4 T cell responses in healthy M. tuberculosis infected South Africans. PLoS Pathog. 12, e1005760 (2016).","journal-title":"PLoS Pathog."},{"key":"1225_CR18","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1046\/j.1365-2249.2003.02201.x","volume":"133","author":"N Caccamo","year":"2003","unstructured":"Caccamo, N. et al. Cytokine profile, HLA restriction and TCR sequence analysis of human CD4+ T clones specific for an immunodominant epitope of Mycobacterium tuberculosis 16-kDa protein. Clin. Exp. Immunol. 133, 260\u2013266 (2003).","journal-title":"Clin. Exp. Immunol."},{"key":"1225_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1128\/CVI.05544-11","volume":"19","author":"FF Yang","year":"2012","unstructured":"Yang, F. F. et al. Monitoring of peptide-specific and gamma interferon-productive T cells in patients with active and convalescent tuberculosis using an enzyme-linked immunosorbent spot assay. Clin. Vaccin. Immunol. 19, 401\u2013410 (2012).","journal-title":"Clin. Vaccin. Immunol."},{"key":"1225_CR20","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.4049\/jimmunol.1103556","volume":"188","author":"CS Arlehamn","year":"2012","unstructured":"Arlehamn, C. S. et al. Dissecting mechanisms of immunodominance to the common tuberculosis antigens ESAT-6, CFP10, Rv2031c (hspX), Rv2654c (TB7.7), and Rv1038c (EsxJ). J. Immunol. 188, 5020\u20135031 (2012).","journal-title":"J. Immunol."},{"key":"1225_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/BF03402042","volume":"9","author":"D Vincenti","year":"2003","unstructured":"Vincenti, D. et al. Identification of early secretory antigen target-6 epitopes for the immunodiagnosis of active tuberculosis. Mol. Med. 9, 105\u2013111 (2003).","journal-title":"Mol. Med"},{"key":"1225_CR22","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s12026-021-09203-6","volume":"69","author":"A Komal","year":"2021","unstructured":"Komal, A., Noreen, M. & El-Kott, A. F. TLR3 agonists: RGC100, ARNAX, and poly-IC: a comparative review. Immunol. Res 69, 312\u2013322 (2021).","journal-title":"Immunol. Res"},{"key":"1225_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1075291","volume":"14","author":"KH Ko","year":"2023","unstructured":"Ko, K. H. et al. A novel defined TLR3 agonist as an effective vaccine adjuvant. Front Immunol. 14, 1075291 (2023).","journal-title":"Front Immunol."},{"key":"1225_CR24","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.3390\/cancers15245752","volume":"15","author":"SH Lee","year":"2023","unstructured":"Lee, S. H. et al. The defined TLR3 agonist, nexavant, exhibits anti-cancer efficacy and potentiates anti-PD-1 antibody therapy by enhancing immune cell infiltration. Cancers (Basel) 15, 5752 (2023).","journal-title":"Cancers (Basel)"},{"key":"1225_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54620-4","volume":"15","author":"KH Ko","year":"2024","unstructured":"Ko, K. H. et al. A vaccine platform targeting lung-resident memory CD4(+) T-cells provides protection against heterosubtypic influenza infections in mice and ferrets. Nat. Commun. 15, 10368 (2024).","journal-title":"Nat. Commun."},{"key":"1225_CR26","doi-asserted-by":"publisher","first-page":"17681","DOI":"10.1074\/jbc.M800123200","volume":"283","author":"KL Lightbody","year":"2008","unstructured":"Lightbody, K. L. et al. Molecular features governing the stability and specificity of functional complex formation by Mycobacterium tuberculosis CFP-10\/ESAT-6 family proteins. J. Biol. Chem. 283, 17681\u201317690 (2008).","journal-title":"J. Biol. Chem."},{"key":"1225_CR27","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1128\/IAI.01990-06","volume":"75","author":"A Geluk","year":"2007","unstructured":"Geluk, A. et al. T-cell recognition of the HspX protein of Mycobacterium tuberculosis correlates with latent M. tuberculosis infection but not with M. bovis BCG vaccination. Infect. Immun. 75, 2914\u20132921 (2007).","journal-title":"Infect. Immun."},{"key":"1225_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2001-2-10-research0044","volume":"2","author":"NC Gey Van Pittius","year":"2001","unstructured":"Gey Van Pittius, N. C. et al. The ESAT-6 gene cluster of Mycobacterium tuberculosis and other high G+C Gram-positive bacteria. Genome Biol. 2, RESEARCH0044 (2001).","journal-title":"Genome Biol."},{"key":"1225_CR29","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S1473-3099(24)00143-9","volume":"24","author":"I Satti","year":"2024","unstructured":"Satti, I. et al. Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial. Lancet Infect. Dis. 24, 909\u2013921 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1225_CR30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1365-2249.2004.02648.x","volume":"138","author":"JA Tree","year":"2004","unstructured":"Tree, J. A. et al. Intranasal bacille Calmette-Guerin (BCG) vaccine dosage needs balancing between protection and lung pathology. Clin. Exp. Immunol. 138, 405\u2013409 (2004).","journal-title":"Clin. Exp. Immunol."},{"key":"1225_CR31","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202217084","volume":"15","author":"A Kang","year":"2023","unstructured":"Kang, A. et al. Subcutaneous BCG vaccination protects against streptococcal pneumonia via regulating innate immune responses in the lung. EMBO Mol. Med 15, e17084 (2023).","journal-title":"EMBO Mol. Med"},{"key":"1225_CR32","doi-asserted-by":"publisher","first-page":"e01686","DOI":"10.1128\/mBio.01686-16","volume":"7","author":"C Perdomo","year":"2016","unstructured":"Perdomo, C. et al. Mucosal BCG vaccination induces protective lung-resident memory T cell populations against tuberculosis. mBio 7, e01686\u201316 (2016).","journal-title":"mBio"},{"key":"1225_CR33","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.4049\/jimmunol.1300283","volume":"192","author":"JS Woodworth","year":"2014","unstructured":"Woodworth, J. S. et al. Protective CD4 T cells targeting cryptic epitopes of Mycobacterium tuberculosis resist infection-driven terminal differentiation. J. Immunol. 192, 3247\u20133258 (2014).","journal-title":"J. Immunol."},{"key":"1225_CR34","doi-asserted-by":"publisher","first-page":"8080","DOI":"10.1021\/acs.jmedchem.9b00832","volume":"62","author":"AS Ashhurst","year":"2019","unstructured":"Ashhurst, A. S. et al. Mucosal vaccination with a self-adjuvanted lipopeptide is immunogenic and protective against mycobacterium tuberculosis. J. Med Chem. 62, 8080\u20138089 (2019).","journal-title":"J. Med Chem."},{"key":"1225_CR35","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1016\/j.vaccine.2016.08.039","volume":"34","author":"ACM Platteel","year":"2016","unstructured":"Platteel, A. C. M. et al. Strategies to enhance immunogenicity of cDNA vaccine encoded antigens by modulation of antigen processing. Vaccine 34, 5132\u20135140 (2016).","journal-title":"Vaccine"},{"key":"1225_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102596","volume":"298","author":"D Kumar Das","year":"2022","unstructured":"Kumar Das, D. et al. Targeting dendritic cells with TLR-2 ligand-coated nanoparticles loaded with Mycobacterium tuberculosis epitope induce antituberculosis immunity. J. Biol. Chem. 298, 102596 (2022).","journal-title":"J. Biol. Chem."},{"key":"1225_CR37","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1128\/IAI.01137-06","volume":"75","author":"V Roupie","year":"2007","unstructured":"Roupie, V. et al. Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice. Infect. Immun. 75, 941\u2013949 (2007).","journal-title":"Infect. Immun."},{"key":"1225_CR38","doi-asserted-by":"publisher","first-page":"5284","DOI":"10.1080\/21645515.2021.2007711","volume":"17","author":"M Qu","year":"2021","unstructured":"Qu, M., Zhou, X. & Li, H. BCG vaccination strategies against tuberculosis: updates and perspectives. Hum. Vaccin Immunother. 17, 5284\u20135295 (2021).","journal-title":"Hum. Vaccin Immunother."},{"key":"1225_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1128\/iai.64.1.16-22.1996","volume":"64","author":"M Harboe","year":"1996","unstructured":"Harboe, M., Oettinger, T., Wiker, H. G., Rosenkrands, I. & Andersen, P. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect. Immun. 64, 16\u201322 (1996).","journal-title":"Infect. Immun."},{"key":"1225_CR40","doi-asserted-by":"publisher","first-page":"6353","DOI":"10.4049\/jimmunol.177.9.6353","volume":"177","author":"J Dietrich","year":"2006","unstructured":"Dietrich, J. et al. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J. Immunol. 177, 6353\u20136360 (2006).","journal-title":"J. Immunol."},{"key":"1225_CR41","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1172\/JCI46252","volume":"122","author":"PL Lin","year":"2012","unstructured":"Lin, P. L. et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J. Clin. Invest 122, 303\u2013314 (2012).","journal-title":"J. Clin. Invest"},{"key":"1225_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00847-7","volume":"9","author":"KW Kwon","year":"2024","unstructured":"Kwon, K. W. et al. BCG-booster vaccination with HSP90-ESAT-6-HspX-RipA multivalent subunit vaccine confers durable protection against hypervirulent Mtb in mice. NPJ Vaccines 9, 55 (2024).","journal-title":"NPJ Vaccines"},{"key":"1225_CR43","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1128\/IAI.68.6.3314-3321.2000","volume":"68","author":"SM Arend","year":"2000","unstructured":"Arend, S. M. et al. Antigenic equivalence of human T-cell responses to Mycobacterium tuberculosis-specific RD1-encoded protein antigens ESAT-6 and culture filtrate protein 10 and to mixtures of synthetic peptides. Infect. Immun. 68, 3314\u20133321 (2000).","journal-title":"Infect. Immun."},{"key":"1225_CR44","doi-asserted-by":"publisher","first-page":"S201","DOI":"10.1086\/313862","volume":"30","author":"AS Mustafa","year":"2000","unstructured":"Mustafa, A. S. et al. Multiple epitopes from the Mycobacterium tuberculosis ESAT-6 antigen are recognized by antigen-specific human T cell lines. Clin. Infect. Dis. 30, S201\u2013S205 (2000). Suppl 3.","journal-title":"Clin. Infect. Dis."},{"key":"1225_CR45","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1046\/j.1365-3083.2003.01204.x","volume":"57","author":"AS Mustafa","year":"2003","unstructured":"Mustafa, A. S. et al. Human Th1 cell lines recognize the Mycobacterium tuberculosis ESAT-6 antigen and its peptides in association with frequently expressed HLA class II molecules. Scand. J. Immunol. 57, 125\u2013134 (2003).","journal-title":"Scand. J. Immunol."},{"key":"1225_CR46","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.4049\/jimmunol.174.4.2174","volume":"174","author":"G Tully","year":"2005","unstructured":"Tully, G. et al. Highly focused T cell responses in latent human pulmonary Mycobacterium tuberculosis infection. J. Immunol. 174, 2174\u20132184 (2005).","journal-title":"J. Immunol."},{"key":"1225_CR47","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.tube.2009.10.003","volume":"90","author":"M Kumar","year":"2010","unstructured":"Kumar, M. et al. Immune response to Mycobacterium tuberculosis specific antigen ESAT-6 among south Indians. Tuberculosis (Edinb.) 90, 60\u201369 (2010).","journal-title":"Tuberculosis (Edinb.)"},{"key":"1225_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45058-9","volume":"15","author":"S Panda","year":"2024","unstructured":"Panda, S. et al. Identification of differentially recognized T cell epitopes in the spectrum of tuberculosis infection. Nat. Commun. 15, 765 (2024).","journal-title":"Nat. Commun."},{"key":"1225_CR49","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/764028","volume":"2014","author":"H Nagai","year":"2014","unstructured":"Nagai, H. et al. Immunological responses and epitope mapping by tuberculosis-associated antigens within the RD1 region in Japanese patients. J. Immunol. Res 2014, 764028 (2014).","journal-title":"J. Immunol. Res"},{"key":"1225_CR50","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1128\/CVI.00322-08","volume":"15","author":"G Li Pira","year":"2008","unstructured":"Li Pira, G. et al. Evaluation of antigen-specific T-cell responses with a miniaturized and automated method. Clin. Vaccin. Immunol. 15, 1811\u20131818 (2008).","journal-title":"Clin. Vaccin. Immunol."},{"key":"1225_CR51","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10875-009-9311-y","volume":"30","author":"K Oswald-Richter","year":"2010","unstructured":"Oswald-Richter, K. et al. Mycobacterial ESAT-6 and katG are recognized by sarcoidosis CD4+ T cells when presented by the American sarcoidosis susceptibility allele, DRB1*1101. J. Clin. Immunol. 30, 157\u2013166 (2010).","journal-title":"J. Clin. Immunol."},{"key":"1225_CR52","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.4049\/jimmunol.173.3.1966","volume":"173","author":"H Shams","year":"2004","unstructured":"Shams, H. et al. Characterization of a Mycobacterium tuberculosis peptide that is recognized by human CD4+ and CD8+ T cells in the context of multiple HLA alleles. J. Immunol. 173, 1966\u20131977 (2004).","journal-title":"J. Immunol."},{"key":"1225_CR53","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.tube.2015.07.005","volume":"95","author":"BR Mothe","year":"2015","unstructured":"Mothe, B. R. et al. The TB-specific CD4(+) T cell immune repertoire in both cynomolgus and rhesus macaques largely overlap with humans. Tuberculosis (Edinb.) 95, 722\u2013735 (2015).","journal-title":"Tuberculosis (Edinb.)"},{"key":"1225_CR54","doi-asserted-by":"publisher","first-page":"e1003130","DOI":"10.1371\/journal.ppat.1003130","volume":"9","author":"CS Lindestam Arlehamn","year":"2013","unstructured":"Lindestam Arlehamn, C. S. et al. Memory T cells in latent Mycobacterium tuberculosis infection are directed against three antigenic islands and largely contained in a CXCR3+CCR6+ Th1 subset. PLoS Pathog. 9, e1003130 (2013).","journal-title":"PLoS Pathog."},{"key":"1225_CR55","doi-asserted-by":"publisher","first-page":"6164","DOI":"10.4049\/jimmunol.1403074","volume":"194","author":"S Paul","year":"2015","unstructured":"Paul, S. et al. A population response analysis approach to assign class II HLA-epitope restrictions. J. Immunol. 194, 6164\u20136176 (2015).","journal-title":"J. Immunol."},{"key":"1225_CR56","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.imlet.2004.11.021","volume":"98","author":"N Caccamo","year":"2005","unstructured":"Caccamo, N. et al. Th0 to Th1 switch of CD4 T cell clones specific from the 16-kDa antigen of Mycobacterium tuberculosis after successful therapy: lack of involvement of epitope repertoire and HLA-DR. Immunol. Lett. 98, 253\u2013258 (2005).","journal-title":"Immunol. Lett."},{"key":"1225_CR57","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1046\/j.1365-3083.1998.00420.x","volume":"48","author":"RJ Wilkinson","year":"1998","unstructured":"Wilkinson, R. J. et al. Human T- and B-cell reactivity to the 16kDa alpha-crystallin protein of Mycobacterium tuberculosis. Scand. J. Immunol. 48, 403\u2013409 (1998).","journal-title":"Scand. J. Immunol."},{"key":"1225_CR58","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1046\/j.1365-2249.1998.00724.x","volume":"114","author":"JN Agrewala","year":"1998","unstructured":"Agrewala, J. N. & Wilkinson, R. J. Differential regulation of Th1 and Th2 cells by p91-110 and p21-40 peptides of the 16-kD alpha-crystallin antigen of Mycobacterium tuberculosis. Clin. Exp. Immunol. 114, 392\u2013397 (1998).","journal-title":"Clin. Exp. Immunol."},{"key":"1225_CR59","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1002\/(SICI)1521-4141(199906)29:06<1753::AID-IMMU1753>3.0.CO;2-B","volume":"29","author":"JN Agrewala","year":"1999","unstructured":"Agrewala, J. N. & Wilkinson, R. J. Influence of HLA-DR on the phenotype of CD4+ T lymphocytes specific for an epitope of the 16-kDa alpha-crystallin antigen of Mycobacterium tuberculosis. Eur. J. Immunol. 29, 1753\u20131761 (1999).","journal-title":"Eur. J. Immunol."},{"key":"1225_CR60","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1002\/(SICI)1521-4141(199909)29:09<2788::AID-IMMU2788>3.0.CO;2-4","volume":"29","author":"KA Wilkinson","year":"1999","unstructured":"Wilkinson, K. A., Hudecz, F., Vordermeier, H. M., Ivanyi, J. & Wilkinson, R. J. Enhancement of the T cell response to a mycobacterial peptide by conjugation to synthetic branched polypeptide. Eur. J. Immunol. 29, 2788\u20132796 (1999).","journal-title":"Eur. J. Immunol."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01225-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01225-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01225-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T18:56:25Z","timestamp":1757271385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01225-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1225"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01225-7","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.-H.K. is the Chief Executive Officer of the NA Vaccine Institute. K.H.K., H.S.B. and S.B.C. are employees of the NA Vaccine Institute. T.S.S. is an employee of Asan Medical Center. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"161"}}